this is the detail related to the Acadia ADC:
USE OF PROCEEDSWe estimate the net proceeds to us from this offering will be approximately $235.8 million ($271.2 million if the underwriters’ option to purchase additional shares is exercised in full), after payment of the estimated underwriting discounts and commissions and estimated offering expenses payable by us. A $10,000,000 increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus supplement, would increase (decrease) the net proceeds to us by approximately $9.5 million, after payment of the estimated underwriting discounts and commissions and estimated offering expenses payable by us.We intend to use the net proceeds from this offering for general corporate purposes, including to fund preparations for the potential commercialization of pimavanserin for the treatment of dementia-related psychosis, if approved for such indication, and working capital. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies. Although we currently have no specific agreements, commitments or understandings with respect to any acquisition or investment, we evaluate acquisition and investment opportunities and may engage in related discussions with other companies from time to time.The amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of our commercialization activities, research and development efforts, the timing of regulatory review and approval of our product candidates, the timing and progress of any partnering efforts, and the competitive environment for our product candidates. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds from this offering. Accordingly, our management will have broad discretion in the application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short term, interest-bearing instruments.
I would say that at the moment they didn't really need to load the cash in this way and in fact they bring home and invest waiting to understand how to allocate them. for sure therefore they have taken advantage of the opportunity of a high quotation on the market to place a smaller quantity of shares with important return of money; evidently he decides to subscribe he is aware that he pays more but enters the shares with important shares; my reading of this operation is that Acadia is quickly starting to sell the entire company to a big company. consequently we know for ourselves what it will mean; this hypothesis for me is standing from the day after the agreement with Acadia of August 2018.
- Forums
- ASX - By Stock
- NEU
- CR for Acadia
CR for Acadia, page-21
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.30 |
Change
-0.090(0.46%) |
Mkt cap ! $2.466B |
Open | High | Low | Value | Volume |
$19.55 | $19.65 | $18.88 | $10.53M | 549.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 4552 | $19.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.30 | 674 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 4552 | 19.150 |
1 | 2806 | 19.140 |
1 | 1018 | 19.120 |
1 | 1159 | 19.110 |
2 | 1196 | 19.100 |
Price($) | Vol. | No. |
---|---|---|
19.300 | 674 | 2 |
19.320 | 1194 | 2 |
19.330 | 1018 | 1 |
19.360 | 1018 | 1 |
19.390 | 1018 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online